Theravance Biopharma, Inc. (TBPH), a diversified biopharmaceutical company, has declined 5.24% in aftermarket trading session. Consequently, TBPH stock is trading at $7.59 at the time of the writing. On Friday, TBPH closed the day $8.01 after declining 5.21% during regular trading hours. The uncertainty regarding clinical trials being performed by the company has made the stock decline continuously during the last few months.
TBPH Q3 2021 Operational Results
On 3rd November, TBPH reported the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $13.19 million against $18.25 million for the same period of 2020. The total costs and expenses bore by the company during the three months was $66.80 million against $94.87 million for the same period of 2020. The net loss suffered by the company during the three months stood at $35.30 million ($0.48 per basic and diluted share) against $73.64 million ($1.16 per basic and diluted share) for the same period of 2020
Financial Guidance for Upcoming Period
TBPH also updated the financial guidance for the complete year 2021. The company expected that the Research and Development expenses for the full year 2021 would stand at $180 million to $190 million. Alongside, there was an expectation that the Selling, General, and Administrative expenses for the full year 2021 would stand in the range of $70 million to $80 million.
Executive Commentary
Rick E Winningham, Chief Executive Officer of TBPH, while commenting on the results said that the quarter under discussion was about executing its strategies to create and implement a new business model. He said that the company is executing against the strategic plan it announced during the mid of September. He said that the focus of the company is on driving the growth of YUPELRI, streamlining R&D investment, and optimizing its asset portfolio to maximize shareholder value.
Future Outlook for TBPH
During the last 6 months, TBPH has declined more than 50%. The prime reason for that could be the negative sentiments associated with stock throughout the period due to the effects the pandemic imparted throughout the period. However, the analysts are hopeful that going forward, the stock is in a good shape to pay back the shareholders with benefits.
